BxPC-3 (ATCC® CRL-1687)

Organism: Homo sapiens, human  /  Tissue: pancreas  /  Disease: adenocarcinoma

Organism Homo sapiens, human
Tissue pancreas
Product Format frozen
Morphology epithelial
Culture Properties adherent
Biosafety Level 1

Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.

Disease adenocarcinoma
Age 61 years
Gender Female
Applications
This cell line is a suitable transfection host.
Storage Conditions liquid nitrogen vapor phase
Images
Clinical Data
female
Genes Expressed
mucin; pancreas cancer specific antigen (pancreas cancer associated antigen); carcinoembryonic antigen (CEA)
Cellular Products
mucin; pancreas cancer specific antigen (pancreas cancer associated antigen); carcinoembryonic antigen (CEA)
Tumorigenic Yes
Effects
Yes, Tumors developed within 21 days at 100% frequency (5/5) in nude mice inoculated subcutaneously with 10(7) cells.
Comments
The cells do not express the cystic fibrosis transmembrane conductance regulator (CFTR).
A CFTR positive pancreatic line, Capan-1 is available (ATCC HTB-79).
Complete Growth Medium The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, ATCC 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum (ATCC 30-2020) to a final concentration of 10%.
Subculturing
Volumes used in this protocol are for 75 cm2 flask; proportionally reduce or increase amount of dissociation medium for culture vessels of other sizes. Corning® T-75 flasks (catalog #430641) are recommended for subculturing this product.
  1. Remove and discard culture medium.
  2. Briefly rinse the cell layer with 0.25% (w/v) Trypsin- 0.53 mM EDTA (ATCC® 30-2101™) solution to remove all traces of serum that contains trypsin inhibitor.
  3. Add 2.0 to 3.0 mL of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).
    Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal.
  4. Add 6.0 to 8.0 mL of complete growth medium and aspirate cells by gently pipetting.
  5. Add appropriate aliquots of the cell suspension to new culture vessels.
  6. Incubate cultures at 37°C.
Subcultivation Ratio: A subcultivation ratio of 1:3 to 1:6 is recommended
Medium Renewal: 2 to 3 times per week
Cryopreservation
Freeze medium: Complete growth medium 95%; DMSO, 5%
Storage temperature: liquid nitrogen vapor temperature
Culture Conditions
Temperature: 37°C
STR Profile
D5S818: 11
D13S317: 11
D7S820: 10,13
D16S539: 9,11
vWA: 14,18
THO1: 9
Amelogenin: X
TPOX: 8
CSF1PO: 13
Name of Depositor MH Tan
Deposited As Homo sapiens
References

Loor R, et al. Use of pancreas-specific antigen in immunodiagnosis of pancreatic cancer. Clin. Lab. Med. 2: 567-578, 1982. PubMed: 6754226

Lan MS, et al. Polypeptide core of a human pancreatic tumor mucin antigen. Cancer Res. 50: 2997-3001, 1990. PubMed: 2334903

Chambers JA, Harris A. Expression of the cystic fibrosis gene and the major pancreatic mucin gene, MUC1, in human ductal epithelial cells. J. Cell Sci. 105: 417-422, 1993. PubMed: 7691840

Tan MH, et al. Characterization of a new primary human pancreatic tumor line. Cancer Invest. 4: 15-23, 1986. PubMed: 3754176

Basic Documentation
Other Documentation
References

Loor R, et al. Use of pancreas-specific antigen in immunodiagnosis of pancreatic cancer. Clin. Lab. Med. 2: 567-578, 1982. PubMed: 6754226

Lan MS, et al. Polypeptide core of a human pancreatic tumor mucin antigen. Cancer Res. 50: 2997-3001, 1990. PubMed: 2334903

Chambers JA, Harris A. Expression of the cystic fibrosis gene and the major pancreatic mucin gene, MUC1, in human ductal epithelial cells. J. Cell Sci. 105: 417-422, 1993. PubMed: 7691840

Tan MH, et al. Characterization of a new primary human pancreatic tumor line. Cancer Invest. 4: 15-23, 1986. PubMed: 3754176